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                               INTRODUCTION 
 
  
Type 1 Diabetes is a common autoimmune endocrine disease in 
children and adolescents. It is a clinical syndrome in which the destruction of 
the pancreatic islet β-cells leads to progressive insulin deficiency and 
hyperglycemia, which in turn gives rise to micro vascular complications 
such as retinopathy, nephropathy, and neuropathy as well as macro vascular 
complications.42 
 
 The presence of auto antibodies targeted against β-cell antigens 
represents the autoimmune character of Type 1 Diabetes (T1D). Due to this 
autoimmune basis, individuals with T1D are at increased risk for the 
development of additional autoimmune disorders compared with the general 
population1. Commonly coexisting immune-mediated disorders are 
Autoimmune Thyroid Disease (AITD), Coeliac Disease (CD), Addison’s 
Disease (AD) and pernicious anaemia.1,2,42,18 These diseases are associated 
with organ-specific autoantibodies: Thyroid peroxidase (TPO)  thyroglobulin 
(TG), TSH receptor autoantibodies with AITD, endomysial  autoantibodies 
and transglutaminase  autoantibodies with CD, and 21-hydroxylase 
  
 
 
autoantibodies with AD. Using these autoantibodies, organ-specific 
autoimmunity may be detected before the development of autoimmune 
clinical disease.2  
 
The most prevalent among these is  thyroid autoimmunity.11,2,28,19 
Its prevalence varies from 8 to 50% depending on the age, sex, and ethnic 
origin of the subjects. In the general population, thyroid autoimmunity is 
more frequent in female subjects and prevalence increases with age. In 
diabetic patients, age and sex distributions are similar, but the prevalence is 
higher and increases with duration of the disease.4  
 
Most patients with thyroid autoimmunity  are asymptomatic25 . 
Even if symptomatic; symptoms may be attributed to diabetes. So, the 
diagnosis of thyroid dysfunction in diabetic patients based solely on clinical 
manifestations can be difficult7. Though not clinically evident, underlying 
hypothyroidism has its own impact on morbidity particularly by 
exacerbating the coexisting dyslipidemia commonly found in type 1 diabetes 
and thus increases the risk of cardiovascular diseases. 
 
 
  
 
 
 
Because of this high prevalence, lack of clinical features and the 
impact on morbidity, most investigators recommend screening children and 
adolescents with type 1 diabetes for autoimmune thyroid disease. Early 
detection has the potential to prevent significant morbidity related to 
unrecognized disease. 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
                                   
                                 
                            AIMS AND OBJECTIVES 
 
 
 To study the prevalence and pattern of thyroid disorders in           
 Type 1 Diabetic patients. 
  
 To find out thyroid autoimmune status among them. 
 
 To correlate thyroid autoimmunity with thyroid dysfunction. 
 
 To assess any age/gender/diabetes duration difference. 
 
 
 
 
 
 
                                   
                               
  
 
 
 
                                  
                           REVIEW OF LITERATURE 
 
 
 
Background and History: 
 
Type 1 diabetes results from a cellular mediated autoimmune   
destruction of the β-cells of the pancreas, leading to absolute insulin    
deficiency. It is frequently associated with other autoimmune diseases and 
autoantibodies1. The most prevalent autoimmune disease in type 1 diabetes 
is Hashimoto’s thyroiditis.41The increased incidence of thyroid 
autoimmunity in type 1 diabetes was first reported in 196320.Since then 
many series have been reported. Thyroid autoimmunity is generally less 
prevalent in blacks than whites for unknown reasons15. The exact prevalence 
of AITD among Indian adolescents with type 1 diabetes is still unknown. 
 
 
 
 
 
  
 
 
Autoimmunity: 
 
               Autoimmunity represents the end result of the breakdown of 
one or more of the basic mechanisms regulating immune tolerance. The 
essential feature of an autoimmune disease is that tissue injury is caused by 
the immunologic reaction of the organism with its own tissues. 
Autoimmunity can be organ specific or non organ specific. The two most 
common organ specific autoimmune diseases are AITD (autoimmune 
thyroid diseases) and T1D ( type 1 diabetes). Organ-specific autoimmune 
diseases can be part of autoimmune polyglandular syndromes (APS). 
 
Type 1 Diabetes (T1D): 
 
 
                The model of T1D is  a chronic autoimmune disease  beginning 
with genetic susceptibility and progressing to autoimmunity leading to 
destruction of β-cells. Insulin autoantibodies are often the first expressed 
autoantibody. Other antibodies are against  islet cell, GAD65, and IA-2. 
These autoantibodies may be present for years before the diagnosis of 
diabetes. Abnormalities of iv and oral glucose tolerance testing precede  the 
diagnosis of overt diabetes and this may persist for years; ultimately leading 
to overt diabetes.2  
  
 
 
 
   Type 1A diabetes(90%) is autoantibody positive ,type 1 B 
diabetes(10%) is autoantibody negative. Type 1 diabetes can present at any 
age , peak age of presentation being puberty. Clinical presentation is with 
features of hyperglycemia, sometimes directly as diabetic ketoacidosis. 
Patients are insulin dependant from the beginning. They develop diabetes 
related macrovascular and microvascular complications. 
 
Type 1 diabetes is commonly associated with other autoimmune 
diseases like AITD, celiac disease and addison’s disease. It can also be seen 
in autoimmune polyendocrine syndromes 1/ 2. 22         
 
           
 
 
 
 
 
 
 
  
 
 
 Stages in development of Type 1 Diabetes40   
 
 
 
Autoimmune thyroid disease(AITD): 
 
 
   The term "autoimmune thyroid disease" is used to describe all 
autoimmune thyroid conditions, including Graves' disease, Hashimoto's 
thyroiditis, and various other disorders (eg, postpartum thyroiditis, most 
cases of silent thyroiditis). The most common presentation is the presence of 
positive antithyroid antibodies in a euthyroid patient.8 The antithyroid 
antibodies can be anti thyroid peroxidase (anti TPO) antibodies or 
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(?Precipitating Event)
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Normal insulin
release 
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loss insulin 
release 
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antithyroglobulin antibodies or anti TSH receptor antibodies.3 Anti TPO 
antibodies and anti Tg antibodies are prevalent in approximately 13% and 
11% of general population respectively but the prevalence is much less in 
blacks; TPOA positivity seen in only 5% of population. 2,15  
 
  Hypothyroidism with or without goiter is more common than 
hyperthyroidism. Hypothyroidism is prevalent in about 4.5 - 5% of the  
population (0.5% clinical and 4.5% subclinical) and hyperthyroidism in 
about 1.3% (0.5% clinical and 0.7% subclinical).15Autoimmune thyroiditis, 
specifically Hashimoto's thyroiditis, is more prevalent in persons with 
various autoimmune and nonautoimmune disorders like congenital rubella 
syndrome and some genetic conditions like Down’s syndrome. It can be a 
part of autoimmune polyendocrine syndromes type 1-3.22 
 
Genetic basis:  
 
                The major histocompatibility complex (MHC) has been 
extensively studied in autoimmune diseases. The highest-risk human 
leukocyte antigen (HLA) genotype for T1D is DR3-DQ2, DR4-DQ8. 
Subjects expressing this genotype have a 5% risk for T1D by 15 yrs of age. 
  
 
 
Cross-sectional analysis in subjects with T1D has shown an association with 
the genotype DR3-DQ2, DR4-DQ8 and the haplotype DR3-DQ2. 2 
 
                        Screening blood donors for TPO autoantibodies has shown an 
association with DR3 and DR5.10 
 
               In families with multiple members affected with T1D and AITD, 
DR3-DQ2 has been linked with AITD and T1D.34HLA DQB1*0401 can be 
a predisposing genetic marker for the development of AITD in patients with 
T1D21. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a non-
HLA susceptibility gene for type 1 diabetes on chromosome 2q33 expressed 
on activated CD4+ and CD8+ T-cell membranes.  Polymorphisms within the 
CTLA-4 gene have been linked to AITD. Polymorphism of  PTPN22 gene 
expressed in T cells has been associated with T1D and Graves disease. The 
MHC I-related gene A (MIC-A) has been associated with T1D2 
 
 
 
 
 
 
 
 
  
 
 
Selected genes associated with T1D and related autoimmune diseases2 
 
Gene Associated diseases 
HLA  
    DR3-DQ2, DR4-DQ8 T1D 
    DR3; DR5 AITD 
    DR3-DQ2 CD 
    DR3-DQ2, DR4-DQ8  AD 
MIC-A T1D,CD.AD 
PTPN22 T1D.AITD,AD 
CTLA-4 T1D, AIT 
 
 
 
Autoimmune polyendocrine syndromes(APS)39,22 
                              These are APS types I, II, III and IPEX. 
 
 
APS type I:  
It is an autosomal recessive condition with mutations in an 
autoimmune-suppressor gene (AIRE, for autoimmune regulator), which 
encodes a transcription factor.  Affected persons will have any two of  the 
following  conditions — mucocutaneous candidiasis, hypoparathyroidism, 
and Addison's disease. Mutations in the AIRE gene cause many other  
autoimmune diseases, and affected patients are at risk for the development of 
multiple additional autoimmune diseases over time, including type 1A 
  
 
 
diabetes(18%), hypothyroidism, pernicious anemia, alopecia, vitiligo, 
hepatitis, ovarian atrophy, and keratitis. 
 
APS II: 
It is also called Schmidt's syndrome characterized by Addison's 
disease plus hypothyroidism.20% of individuals can develop type 1 diabetes. 
The syndrome is associated with HLA DR3/DR4. 
 
APS III:  
Autoimmune polyendocrine syndrome type III refers to thyroid 
autoimmunity plus another autoimmunity (but not Addison's disease) 
 
IPEX: (Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked)    
               Extremely rare disorder with  X linked inheritance  characterized 
by fulminant, widespread autoimmunity and type 1A diabetes. 
 
 
 
 
 
  
 
 
Effect of Diabetes on Thyroid function: 
 
 There is inter-dependence between insulin and thyroid hormones for 
normal cellular metabolism so that diabetes mellitus and thyroid diseases 
can mutually influence the other disease process.18 
 
 In euthyroid individuals with diabetes mellitus, the serum T3 levels, 
basal TSH levels and TSH response to thyrotropin releasing hormone (TRH) 
may all be strongly influenced by the glycemic status. Poorly controlled 
diabetes, both Type 1 and Type 2, may induce a “Low T3 state”16 
characterized by low serum  total and free T3 levels, increase in reverse T3 
(rT3) but  near normal serum T4 and TSH concentrations.Low serum T3 is 
due to reduced peripheral conversion of thyroxine (T4) to tri-iodothyronine 
(T3) via 5’  monodeiodination reaction. Studies indicate that it may  be the 
long term diabetic control that determines the  plasma T3 levels . Poorly 
controlled diabetes may  also result in impaired TSH response to TRH or 
loss of  normal  nocturnal TSH peak. TSH responses and “low  T3 state” 
may normalize with improvement in glycemic  status but even with good 
diabetes control, the normal  nocturnal TSH peak may not be restored in    
  
 
 
C-peptide  negative patients i.e. those with totally absent  pancreatic beta 
cell function.18 
 
Diabetes mellitus influences the assessment of thyrotoxicosis by 
falsely decreasing the blood levels of thyroxine (T4) and triiodothyronine 
(T3) during severely uncontrolled hyperglycemia. 26 
 
Metabolic effects of Thyroid dysfunction on Diabetes: 
 
The presence of thyroid dysfunction may affect diabetes control. 
Hyperthyroidism is typically associated with worsening glycemic control 
and increased insulin requirements17. There is underlying increased hepatic 
gluconeogenesis, rapid gastrointestinal glucose absorption, increased insulin 
degradation, and probably increased insulin resistance. Indeed, 
thyrotoxicosis may unmask latent diabetes.26In practice, there are several 
implications for patients with both diabetes and hyperthyroidism. First, in 
hyperthyroid patients, the diagnosis of glucose intolerance needs to be 
considered cautiously, since the hyperglycemia may improve with treatment 
of thyrotoxicosis. Second, underlying hyperthyroidism should be considered 
in diabetic patients with unexplained worsening hyperglycemia. Third, in 
  
 
 
diabetic patients with hyperthyroidism, physicians need to anticipate 
possible deterioration in glycemic control and adjust treatment accordingly. 
Restoration of euthyroidism will lower blood glucose level. 
 
Although wide-ranging changes in carbohydrate metabolism are 
seen in hypothyroidism, clinical manifestation of these abnormalities is 
seldom conspicuous.25The synthesis and release of insulin is decreased but 
there is reduced rate of insulin degradation that may lower the exogenous 
insulin requirement.  The rate of hepatic glucose output is decreased 
probably due to reduced gluconeogenesis. The net effect is an increased risk 
of recurrent hypoglycemia in a diabetic individual. 18,13 
 
More importantly, hypothyroidism is accompanied by a variety of 
abnormalities in plasma lipid metabolism, including elevated triglyceride 
and low-density lipoprotein (LDL) cholesterol concentrations. Even 
subclinical hypothyroidism can exacerbate the coexisting dyslipidemia 
commonly found in diabetes and further increase the risk of cardiovascular 
diseases.7,32 
 
  
 
  
 
 
Diabetes and Thyroid diseases – Interactions: 
 
 
 
 
Clinical Condition Effect on Glycemia Effect onThyroid function 
Diabetes mellitus - 
In euthyroid individuals -- 
↓ Serum T3 ↑ rT3 ;          
↓ TSH response to 
TRH;  impaired                
nocturnal TSH peak. 
Hyperthyroidism - In 
euglycemic individuals 
 
Glucose intolerance -  
in 50% cases                    
Overt diabetes in 2-3% 
 
Hyperthyroidism- In 
diabetic individuals 
 
Deterioration of  -
diabetes control 
High incidence of  optic 
neuropathy 
 
Hypothyroidism- In 
diabetic individuals 
 
Predisposition to -
recurrent 
hypoglycemia. 
Exacerbation of 
dyslipidemia. 
 
 
 
                                    
 
 
 
 
 
 
 
  
 
 
 
Thyroid disorders in Type 1 Diabetes: 
                                                                                                               
Prevalence pattern: 
The prevalence of thyroid autoimmunity and thus thyroid 
dysfunction is high in T1D. 15 to 30% of subjects with type 1 diabetes 
(T1D) have autoimmune thyroid disease. 2,3,9,12 
 
As in general population autoimmune thyroid diseases are common 
in females and prevalence increases with age.10,15,19,23 Additionally, 
prevalence increases with increasing duration of Diabetes. 4,9,23   
 
Thyroid autoimmunity is considered to be present if the patient is 
positive for Thyroid peroxidase (TPO) or thyroglobulin (TG) or TSH 
receptor autoantibodies. Among these thyroid peroxidase antibody (TPOA) 
is a very sensitive marker.11 TgAb alone in the absence of TPOA is not 
significantly associated with thyroid disease.15 The presence of GAD 
antibodies in T1D was associated with an almost two-fold greater risk of 
thyroid autoimmunity than  in the absence of GAD seroreactivity.20,33,34  
There is an  increased frequency of thyroid dysfunction in siblings of  
  
 
 
 
diabetic patients also.41,14 One-third of women with type 1 diabetes will 
develop post partum thyroiditis. 37 
 
Thyroid autoimmunity manifests commonly as hypothyroidism. 
But,hypothyroidism has a lower prevalence than thyroid autoimmunity  
according to most studies. This is because, it may take years for patients with 
positive autoimmune serology to develop thyroid disease.12 With follow-up 
of almost 20 yrs, the development of hypothyroidism in the population with 
T1D and TPO autoantibodies approached  80% in life table analysis.2 
Patients who were TPO positive were almost 18 times as likely to develop 
hypothyroidism as patients who were TPO negative.6,12,25 
 
Hyperthyroidism is much less commonly reported, with a prevalence 
similar to general population rates of 1% . 
 
 
 
 
 
  
 
 
Clinical aspects: 
 
T1D patients with AITD may belong to a subgroup of diabetic 
patients with severe form of diabetes which is characterized by a higher 
prevalence of  ketoacidosis.28 
 
Most of the  diabetic  patients are asymptomatic at diagnosis of 
hypothyroidism25 ie. most of them have only subclinical hypothyroidism. 
Even if symptomatic; symptoms can easily be misinterpreted to be due to 
underlying diabetes because people with this condition may experience 
fatigue, weight gain, feeling cold, dry skin and hair,  constipation and 
slowed thinking. T1D can also produce menstrual disturbances by itself, thus 
misleading. 27 Edema, fatigue, pallor, and weight gain can be attributed to be 
due to diabetic nephropathy.7 
 
Symptoms of hyperthyroidism in people with type 1 diabetes can 
produce symptoms like weight loss despite increased appetite and fatigue 
and may be attributed to poor glycaemic control.  
 
  
 
 
So, both hypo and hyperthyroidism can go unnoticed clinically 
necessitating other methods for diagnosis. Apart from controlling morbidity 
related to thyroid dysfunction, early diagnosis is particularly essential to 
prevent the adverse impact of these disorders in diabetic individuals. 
Screening for thyroid dysfunction may prevent the development of overt 
thyroid dysfunction and may allow early treatment of 
hyperlipidemia,prevention of associated cardiovascular complications , and 
metabolic bone disorders. 
 
  Thyroid peroxidase antibodies is more sensitive than other 
antibodies in identifying thyroid autoimmunity.15,11 So screening for TPOA 
helps in finding out those with AITD. Thyroid ultrsonogram abnormality 
was a sensitive but non-specific marker of AITD and is therefore unsuitable 
for screening purposes.30  
 
The availability of the highly sensitive immunoassay for serum TSH 
(with detection limit of <0.1 mU/l) provides a major advance in the 
diagnosis of thyroid disorders. It is the most reliable and sensitive screening 
test for thyroid dysfunction and allows both hypothyroidism and 
hyperthyroidism to be diagnosed with certainty. In addition, subclinical 
  
 
 
thyroid dysfunction can only be diagnosed by an abnormal TSH because the 
serum T3 and T4 are normal and, by definition, the patients are usually 
asymptomatic. 7 
 
The American Diabetes Association  and several 
authors.7,14,16,17,18,23 recommend annual screening for thyroid disease in all 
type 1 diabetes subjects. TSH measurement is considered the most sensitive 
way to identify patients with thyroid dysfunction, as autoantibodies may 
persist for many years without thyroid dysfunction.4 However, the presence 
of thyroid autoantibodies increases the risk for thyroid disease and so 
particularly those with positive TPO antibodies should undergo screening. 
Despite the association between positive thyroid TPO antibodies and the 
subsequent development of hypothyroidism, annual measurement of serum 
TSH constitutes the preferred screening test to detect asymptomatic thyroid 
dysfunction.25  
 
 
 
 
  
 
 
                      
                      MATERIALS AND METHODS  
 
Study design: 
 
                 Cross sectional observational study to analyse the prevalence of 
thyroid disorders and thyroid autoimmunity among Type 1 Diabetes. 
 
Setting:  
                 Institute of Internal Medicine and Department  of  
                                                                       Diabetology ,                                                        
                 Government General Hospital,   
                 Madras Medical College, 
                 Chennai. 
 
Approval:  
                The study was approved by the ethical committee of Government 
General Hospital, Madras Medical College. 
 
 
  
 
 
 
Study population: 
 
                Patients were enrolled from the patient population who attended 
the out patient clinic of Department of Diabetology and Institute of Internal 
Medicine between Nov. 2005 to Feb 2007. 64 patients among them satisfied 
criteria for inclusion into the study. Patient list did not include paediatric 
group since they were not attending our hospital. 
 
No. of patients enrolled   :  71 
No. of patients included  :  64 
No. of patients excluded  :   7 
 
Inclusion criteria:  
                    Established cases of Type 1 Diabetes , diagnosed based on standard 
criteria [ Symptoms of diabetes and a casual plasma glucose 200 mg/dl 
(11.1 mmol/l) or  FPG 126 mg/dl (7.0 mmol/l) or  2-h plasma glucose 200 
mg/dl (11.1 mmol/l) ] and insulin dependance proved by C peptide level of    
< 1 ng/ml. 
 
  
 
 
 
 
Exclusion criteria: 
 Pregnancy 
 Evidence of other autoimmune diseases like Addisons disease, 
vitiligo, autoimmune hepatitis, rheumatoid arthritis,SLE. 
 Multinodular goiter, known thyroid disease with negative 
thyroid autoimmunity. 
 Past history of thyroid surgery or radioiodine therapy. 
 
`Consent: 
               Patients were informed about the details of the test performed and 
blood sample collected with consent. 
 
Sample collection: 
               Venous blood sample collected in 8 hrs fasting state.               After 
serum separation, sample was sent for analysis. 
 
 
 
  
 
 
         
Method of testing: 
 
            T3,T4, TSH             --         Radio Immuno Assay. 
            Thyroid peroxidase  --         Enzyme Linked Immuno 
            Antibodies                           Sorbent Assay.  
 
 Normal ranges: 
T3         0.8 –  1.4  ng/ml 
T4         4.2 – 11    µg/dl 
TSH      0.5 – 5      mIU/ ml 
TPOA    upto 40    IU/ml 
 
 
 
 
 
 
 
 
 
  
 
 
 
Result interpretations: 
` 
¾ Any T3 /T4 value above the upper limit of normal along with a low 
TSH < 0.5 mIU/ml is considered as hyperthyroidism. 
¾ Any T3 /T4 value below the lower limit of normal along with an 
elevated TSH > 5mIU/ml is considered as hypothyroidism. 
¾ TSH > 5mIU/ml along with normal range T3 , T4 is considered as 
subclinical hypothyroidism. 
¾ TSH < 0.5 mIU/ml along with normal range T3 , T4 is considered as 
subclinical hyperthyroidism. 
¾ Thyroid autoimmunity is considered to exist if TPOA level is > 40 
IU/ml and not to exist if it is lesser. 
 
 
 
 
 
 
 
  
 
 
 
Statistical analysis: 
 
         Statistical analysis was done using standard formulae SPSS 
(Statistical Package for Social Sciences) in windows Dos version. 
           
Base line data like age, gender, duration of diabetes were collected. 
Patients were categorized based on their thyroid status and thyroid 
autoimmune status. 
          The significance of difference between means in two groups 
was calculated using student t test and the significance of difference in 
proportions using chi-square test. Fisher exact test was used when any one of 
the values was less than 5 in chi-square test.  2 x 2 tables were constructed 
for each variable and chi square value for a degree of freedom calculated. 
Statistical significance at 5% levels was taken for  p value < 0.05 and at 1% 
levels p < 0.001. 
 
 
 
                   
                    
  
 
 
                        
 
                  OBSERVATIONS AND RESULTS  
 
 
TOTAL NUMBER OF PATIENTS (n)             : 64 
 
                                            FEMALE              : 33 
                                                MALE               : 31 
                                                  AGE                : 13-32 YEARS 
                                                                    (MEAN - 20.2 + 5.16) 
 
 
 
TOTAL NO. OF HYPOTHYROID PATIENTS                 : 8 (12.5%) 
                                                             MALE                     : 2 
                                                         FEMALE                     : 6 
              SUBCLINICAL HYPOTHYROIDISM                 : 7 
                         OVERT HYPOTHYROIDISM                   : 1 
 
TOTAL NO. OF HYPERTHYROID  PATIENTS.             : NIL 
  
  
 
 
 
TOTAL NO. OF PATIENTS POSITIVE FOR TPOA 
                                      ie. PATIENTS WITH AITD.        : 12 (18.75%) 
                                                                       MALE          : 4 
                                                                   FEMALE         : 8   
 
TOTAL NO. OF TPOA PATIENTS WITH 
                                                 HYPOTHYROIDISM        : 7 out of 12   
                                                                                            (58%) 
 
 
TOTAL NO. OF HYPOTHYROID PATIENTS WITH  
                                                                        TPOA           : 7 out of 8       
                                                                                            (87.5%) 
 
 
 
MEAN AGE OF PATIENTS WITH AITD                       : 21.2 + 5.6 YRS 
 
MEAN DURATION OF DIABETES OF PATIENTS 
WITH AITD                                                                       : 4.5 + 3.5 YRS 
 
 
 
 
 
  
 
 
 
 
 
 
TABLE 1 :  THYROID STATUS IN RELATION TO GENDER. 
 
 
 
GENDER 
 
THYROID 
STATUS 
 
TOTAL NO. 
(IN%)  
MALE 
 
FEMALE 
 
EUTHYROID 
 
56 
(87.5%) 
 
29 
(45.3%) 
 
27 
(42.2%) 
 
HYPOTHYROID 
 
8 
(12.5%) 
 
2 
(3.1%) 
 
6 
(9.4%) 
 
HYPERTHYROID 
 
nil 
  
 
 
 
                  On comparing the female : male 3:1 ratio by chi square test , the 
p value  is  0.1573 which is > 0.05 . So, the association between gender and 
hypothyroidism is  not significant  indicating that there is no significant 
gender difference among hypothyroid and euthyroid type 1 diabetics as per 
this study. 
 
 
 
  
 
 
CHART 1: THYROID STATUS IN RELATION TO GENDER IN 
ACTUAL NUMBERS. 
29
27
2
6
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CHART 2 : THYROID STATUS IN RELATION TO GENDER IN 
PERCENTAGE. 
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TABLE 2: THYROID AUTOIMMUNITY STATUS IN RELATION TO 
GENDER. 
 
 
 
GENDER 
 
THYROID 
AUTOIMMUNITY 
 
    TOTAL 
    (IN %)  
MALE 
 
FEMALE 
 
TPOA 
NEGATIVE 
 
 
 
52 
(81.25%) 
 
 
27 
(42.25%) 
 
 
25 
(39%) 
 
TPOA 
POSITIVE 
 
 
12 
(18.75%) 
 
 
4 
(6.25%) 
 
 
8 
(12.5%) 
 
 
 
 
               On comparing the female : male ratio 2:1 by chi square test , the p 
value  is  0.2482 which is > 0.05 . So, the association between gender and 
thyroid autoimmunity is  not significant  indicating that there is no 
significant gender difference among those who are positive for TPOA and 
those who are negative for the same in type 1 diabetics as per this study. 
 
 
 
 
  
 
 
CHART 3: THYROID AUTOIMMUNE STATUS IN RELATION TO 
GENDER IN ACTUAL NUMBERS. 
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CHART 4: THYROID AUTOIMMUNE STATUS IN RELATION TO 
GENDER IN PERCENTAGE. 
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TABLE 3 : CORRELATION BETWEEEN THYROID FUNCTION AND 
AUTOIMMUNITY. 
 
 
 
 
CATEGORY 
 
HYPOTHYROID
 
EUTHYROID 
 
TOTAL 
 
TPOA 
POSITIVE 
 
7 
(58%) 
 
5 
(42%) 
 
12 
 
TPOA 
NEGATIVE 
 
1 
(2%) 
 
51 
(98%) 
 
52 
 
TOTAL 
 
8 
 
56 
 
64 
 
Values in brackets represent row percentage. 
 
 
        58% of TPOA positive patients are hypothyroid whereas only 2% of 
TPOA negative patients are hypothyroid. 87.5% of hypothyroid patients are 
TPOA positive whereas 12.5% of them are TPOA negative. On comparing 
these two values by       chi square test , the p value is 0.001 which is 
statistically significant at 1% levels. So, the association between thyroid 
autoimmunity and hypothyroidism is significant indicating that 
hypothyroidism is more prevalent among TPOA positive individuals than in 
TPOA negative individuals. 
  
 
 
 
 
CHART 5: CORRELATION BETWEEN THYROID FUNCTION AND THYROID 
AUTOIMMUNITY. 
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51(98%)
1(2%)
 
 On assessing TPOA status as a predictor for development of thyroid 
dysfunction , the positive predictive value is 58% and the negative predictive 
value is 98% 
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TABLE 4: THYROID AUTOIMMUNITY IN RELATION TO DURATION 
OF DIABETES. 
 
 
 
   AUTOIMMUNE STATUS  
 
   MEAN DURATION OF DIABETES 
                      IN YEARS + SD 
 
TPOA POSITIVE 
 
4.5 + 3.5 
 
TPOA NEGATIVE 
 
3.2 + 1.9 
 
 
 
            On comparing the the two means by student t test , the p value is 
0.081 whish is < 0.05. So, the association between thyroid autoimmunity 
and duration of diabetes is not significant indicating  that prevalence of 
AITD is not related to duration of diabetes as per this study. 
 
 
 
 
  
 
 
 
 
 
 
TABLE 5: THYROID AUTOIMMUNITY IN RELATION TO AGE OF 
THE PATIENTS. 
 
 
 
THYROID AUTOIMMUNITY 
 
MEAN AGE IN YEARS 
+ SD 
 
TPOA POSITIVE 
 
21.2 + 5.6 
 
TPOA NEGATIVE 
 
20 + 5 
 
 
 
On comparing the two means by student t test, the p value is 0.478 . 
So, the association between prevalence of thyroid autoimmunity and age of 
diabetics is not significant, indicating that prevelance of AITD is not related 
to age of  the patients as per this study. 
 
 
 
 
 
  
 
 
 
INTERPRETATION OF RESULTS:  
 
¾ Most of the TPOA positive individuals have abnormal thyroid 
function. Positive predictive value is 58%. 
 
¾ Abnormal thyroid function is mainly in the form of subclinical 
hypothyroidism. 
 
¾ Hypothyroidism is more common among those who are 
positive for TPOA; however hypothyroidism is seen in TPOA 
negative subjects also. 
 
¾ Though the actual numbers are high, there is no statistically 
significant difference in age, sex, duration of diabetes between 
TPOA positive and TPOA negative individuals. 
 
 
 
 
  
 
 
 
 
                                 DISCUSSION 
 
Prevalence of Thyroid autoimmunity in Type 1 Diabetes: 
 
   We confirmed the high prevalence of a second organ-specific 
autoimmune manifestation in individuals with type 1 diabetes. By cross –
sectional analysis the prevalence of thyroid autoimmunity in our study 
population is 18.75%. (12 out of 64). This is in concordance with many 
other similar studies from various parts of the world. Most of the studies 
state the prevalence to be between 15 to 30%. Roldán MB et al 11 -17.6%; 
Prázný M17 - 22%, McCanlies E43-26.6% , Maugendre D et al19 -17% 
 
Initial screening of type 1 diabetic patients at the time of diagnosis, 
for the presence of thyroid antibodies was done by Gemma et al in march 
20074 and O Kordonouri et al23 in 2005 and they found out TPOA positivity 
in 14.2% and 15.4% respectively. 
 
  
 
 
Study by Aaron Hanukoglu et al41 is a multicentered cross sectional 
study which included both newly diagnosed as well as previously diagnosed 
patients .They give the prevalence as 27%.                         
Same study says the prevalence in first degree relatives as 25%. Similar 
single time measurement of antibodies was done by Jennifer M. Barker et 
al34 which showed the prevalence as 29%. They  actually found an 
association between thyroid autoimmunity and positivity for Anti GAD 
antibodies & HLA DR3-DQ2 homozygosity. Comparable value of 26% and 
a similar HLA association was given by Kim EY et al.21 
 
Many longitudinal studies have shown a still higher prevalence due 
to late appearance of thyroid peroxidase antibodies. Adriana Franzese et el28 
diagnosed 50% of AITD patients at initial screening , remaining 50% on 
follow up. Longitudinal study by Guillermo E. Umpierrez et al6 has shown it 
to be 33% but most of tested positive in the beginning itself. 
 
A study by Menon et al35, conducted in Department of Pediatrics, 
All India Institute of Medical Sciences, New Delhi in 2001, is the only 
Indian study available in this context. According to this study TPO 
  
 
 
prevalence is 54.3%. This is a higher value when compared to our study as 
well as many other studies. But the limitation of this study is that, only 35 
patients were included. 
 
Sarah J. Glastras et al12 and D Hansen et al30 give relatively lower 
values of 7.8% and 12.9% respectively. 
 
While most of the studies included patients of any age, the one by   
Miguel Fernandez-castaner et al 38 is similar to ours. They included only 
adult population of age > 14 years and found out the prevalence to be 27.9% 
 
Thus, our study on type 1 diabetes supports previous studies in 
terms of AITD prevalence. 
 
 
 
 
 
 
 
  
 
 
 
Prevalence of Thyroid dysfunction in Type 1 Diabetes: 
            
The reported prevalence of thyroid dysfunction in diabetic 
populations varies widely between studies. But, thyroid dysfunction is seen 
particularly in those who are positive for thyroid autoimmunity and so the 
presence of thyroid autoimmunity is considered to predict the future 
development of thyroid dysfunction. 
 
O Kordonouri et el23 performed a long term, large scale study, 
which included 659 T1D patients . The cumulative incidence of 
hypothyroidism at 10 years of observation time was 0.69 (0.08) in positive 
anti- TPO compared with 0.12 (0.05) in 539 patients with negative anti-TPO 
measurements (p < 0.001) 
 
Guillermo E. Umpierrez et al6 showed a prevalence of thyroid 
dysfunction to be 33%. All patients had hypothyroidism mostly subclinical. 
None had hyperthyroidism. 80% of them were positive for TPOA 
antibodies. Among the TPOA positive individuals, 83% of females and 51% 
of males developed hypothyroidism on follow up. In their study, TPOA 
  
 
 
positivity as a predictor for development of thyroid dysfunction was 
assessed and they found out  67% positive predictive value and a 90% 
negative predictive value. As per their study, patients who were TPO 
positive were 17.91 times as likely to develop hypothyroidism as patients 
who were TPO negative (95% CI 3.89–82.54).  
Comparison with study by Guillermo E. Umpierrez et al: 
  
GUILLERMO E. 
UMPIERREZ 6 
 
OUR STUDY 
 
n 
 
58(F-32,M-26) 
 
64(F-33,M-31) 
 
Prevalence of 
thyroid dysfunction 
 
             33% 
 
           12.5% 
 
TPOA positivity in  
patients with abnormal 
thyroid function 
 
80% 
 
87.5% 
 
Positive predictive   
value of TPOA 
 
67% 
 
58% 
 
Negative predictive 
value of TPOA 
 
90% 
 
              98% 
 
Our study is comparable to this study in all terms except that this 
study was a longitudinal study, where they did assessment for TPOA every 4 
years and thyroid function on yearly basis.  
  
 
 
Miguel Fernandez-castaner38 investigated 111 adult T1D patients 
and found 15.3% thyroid dysfunction , and all of them were positive for 
thyroid antibodies . None of the TPOA negative individuals developed 
thyroid function abnormality. Similarly in the report by Maugendre D et al 
19 24% had abnormal thyroid function among anti-TPO positive patients, 
while none among those who were negative for the antibody. Gemma C et al 
is in favour with this. 
 
Actually, as seen in many studies, hypothyroidism occurs in TPOA 
negative individuals also. This may be due to unknown reasons or due to 
alternative etiologies. Sarah J. Glastras12 reported 46%  thyroid dysfunction 
among TPOA positive patients whereas it was  3.6% in negative patients. In 
our study 2% of TPOA negative patients are hypothyroid. This warrants 
screening all T1D for thyroid function irrespective of their thyroid 
autoimmune status. 
 
In the Indian study by  Menon PS et al35 abnormal thyroid function 
was found in only 1 among 19 TPOA patients . 
 
  
 
 
Similar to the report by Guillermo E. Umpierrez et al 6, all our 
patients with thyroid dysfunction had only hypothyroidism. Most of them 
were subclinical.While we didn’t find any hyperthyroid patients, 
hyperthyroidism has been reported as a presentation of thyroid 
autoimmunity in T1D in several studies. 4,11,28 
 
In the study by Gemma C4 et al, 72% of patients with thyroid 
autoimmunity developed thyroid dysfunction. 68% hypothyroidism, 4% 
hyperthyroidism. Roldán MB et al11 found  11% subclinical hypothyroidism, 
3% overt hypothyroidism, 3% subclinical hyperthyroidism and 6%  overt 
hyperthyroidism  among those who were positive for AITD. Adriana 
Franzese et al28  investigated 37 DM1 patients with TPO-AB, the prevalence 
of hypothyroidism was 16% and that of hyperthyroidism was 4% among 
them. 
 
On the whole, in agreement with many similar reports, we 
observed a higher prevalence of thyroid dysfunction mostly as subclinical 
hypothyroidism in type 1 diabetes than in the general population, especially 
in patients with positive TPO antibodies. 
  
 
 
 
Thyroid autoimmunity in relation to gender: 
 
  Generally thyroid autoimmunity is more common in females than 
in males, this holds good for T1D also as per many cross-sectional as well as 
prospective studies. But there are studies which showed equal prevalence in 
both the gender. In our study, though the actual number of females was high, 
with a F: M ratio of 2:1, it was not of statistical significance. This may be 
due to two reasons. 1. Actual prevalence being equal; 2. Smaller study 
population. 
 
 Gemma C et al 4 reported female preponderance. 18.3% females 
had AITD whereas it was 7% in males. Olga Kordonouri et al9 showed a 
similar female preponderance and they had 63% of AITD patients as 
females. 
 
Reports by Holl RW et al10 O Kordonouri et al23  Adriana 
Franzese et al28 Jennifer M. Barker et al34support this gender difference. 
 
  
 
 
 Miguel Fernandez-castaner et al38 investigated 814 T1D patients 
and found a female predominance among TPOA positive patients but not 
among Tg - Ab positive patients. 
 
Guillermo E. Umpierrez et al 6 found a higher incidence of 
hypothyroidism in TPO positive females than in antibody positive males, but 
reported the prevalence of thyroid autoimmunity as equal in both the sex.   
 
Menon PS et al35 showed that sex doesn’t influence the 
development of thyroid autoimmunity  among Indian paediatric population. 
 
Sarah J. Glastras et al12 D Hansen, FN Bennedbaek et al30 D 
Hansen Penny R et al31 Aaron Hanukoglu et al 41 Maugendre D et al19 are in 
agreement with equal prevalence in both the sex. 
 
As in general population, thyroid autoimmunity is expected to be 
more common in females, but it may not be so in all population. 
 
 
  
 
 
 
Thyroid autoimmunity in relation to age:  
 
Many studies have shown that the prevalence of thyroid 
autoimmunity is high among older patients than younger patients. But in our 
study we didn’t find a significant age difference between TPOA positive and 
TPOA negative individuals. This may be because of the reason that we 
included only patients of age >12. But there are reports, where presence of 
TPOA is not influenced by age . 
 
Olga Kordonouri et al9 states that the prevalence of significant 
thyroid antibody titers increases with increasing age of patients and reached 
its maximum in the 15- to 20-year age group. Holl RW et al10  found the 
prevalence of AITD to increase dramatically with age. O Kordonouri R, 
Hartmann et al 23 reports the prevalence to be high in > 12 years age group. 
Jennifer M. Barker et al34 Czerniawska E et al 25 agree the higher prevalence 
in older age. 
 
  
 
 
In the study by Gemma C et al4  there is a significant age 
difference between those who develop thyroid dysfunction and those who 
remain euthyroid among the TPOA positive subjects. Thyroid function 
abnormality being more common among those who were older at the onset 
of diabetes. But age of onset does not influence the positivity for the 
antibodies. 
 
   Guillermo E. Umpierrez et al,6  Sarah J. Glastras et al ,12   DHansen 
et al 30 Maugendre D et al 19 observed no significant age difference.  
      
            The Indian study by Menon PS  et al35  did not analyse the age 
difference . 
 
Gregory Goodwin et al 1 is totally against other reports by stating 
that the risk of thyroid autoimmunity is more in sibling pairs with younger 
age of onset of diabetes. 
 
The influence of age of onset of diabetes or age of the patient on 
development of AITD may/may not be there depending on the population. 
  
 
 
 
Thyroid autoimmunity in relation to duration of diabetes: 
 
 According to many prospective studies incidence of thyroid 
autoimmunity increases as years pass by since the diagnosis of diabetes. The 
net result would be a higher prevalence of AITD among patients with longer 
duration of diabetes than the newly diagnosed cases. But in our study there 
is no significant difference in duration of diabetes between, TPOA positive 
and TPOA negative persons. This has also been confirmed in many 
longitudinal as well as cross-sectional  studies.  
 
D Hansen et al30, Maugendre D et al19 showed that the duration of 
diabetes doesn’t influence development of AITD. The Indian study by 
Menon PS. 35 et al also observed that the  thyroid autoimmunity did not 
change with duration. 
 
 In the report by Guillermo E. Umpierrez et al6  most subjects with 
positive TPO antibodies (17 of 18) tested positive at the beginning of the 
study and remained positive throughout the study period. Only one patient 
  
 
 
with an initial negative TPO titer developed low-TPO titer after 12 years of 
follow-up. 
  
 In the prospective study by Gemma C et al 4, TPOA was measured 
only at the onset of diabetes. Future conversion to positivity was not 
assessed. But only one of the initial TPOA negative individuals developed 
hypothyroidism who later turned out to be positive for antibody. 
 
According to Olga Kordonouri et al9 prevalence increases with 
increasing duration. O Kordonouri, R Hartmann et al23 and Jennifer M. 
Barker et al34  favour the same. Adriana Franzese et al 28 found a higher 
prevalence in those with longer duration  particularly when they are in 
peripubertal age group. 
 
Whether thyroid autoimmunity prevalence is higher in patients with 
longer duration of diabetes needs further clarification by longitudinal 
analysis. 
 
 
 
  
 
 
                                
                                    CONCLUSIONS   
 
¾ There is a high prevalence of thyroid autoimmunity in individuals 
with type 1 diabetes. A subset of patients develops thyroid 
dysfunction.  
 
¾ Prevalence of thyroid autoimmunity as indicated by TPOA positivity 
is more than that seen among general population.  
 
¾ Prevalence of hypothyroidism is more than that seen among general 
population. (last two interpretations are based on comparisons done 
using standard publications15) 
 
¾ Most of the patients develop subclinical form of the disease thus 
reducing the possibility of clinical suspicion.  
 
¾ Gender, age and duration of diabetes may or may not have a 
significant association with autoimmune thyroid disease. 
 
  
 
 
 
¾ In summary, our study confirms the association between 
autoimmune hypothyroidism and type 1 diabetes and suggests that 
all subjects with type 1 diabetes, particularly those with positive 
TPO antibodies, should undergo annual screening by serum TSH 
measurement to detect asymptomatic thyroid dysfunction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         
  
 
 
                      
 
                      SCOPE FOR FUTURE STUDIES 
 
 
Organ-specific autoantibodies provide a simple way to screen for 
autoimmunity in the  susceptible population and possibly prevent morbidity 
and mortality. However, the specific strategy for screening is an area of 
active debate and research . Long-term prospective studies are needed to 
identify the natural history of autoimmunity in patients with type 1 diabetes. 
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                                              PROFORMA 
 
 
 
          NAME     : 
          SEX      : 
          AGE     : 
          DURATION OF DIABETES : 
          SYMPTOMS/SIGNS    
                OF HYPOTHYROIDISM   : 
          SYMPTOMS/SIGNS  
             OF HYPERTHYROIDISM : 
          CO EXISTING MEDICAL 
                                      ILLNESS    : 
          THYROID PROFILE   
                           TOTAL T3   : 
                            TOTAL T4   : 
                            TSH    : 
          TPO ANTIBODY           : 
  
 
 
                                 MASTER CHART 
 
 
 
S.NO Age Sex Diabetes 
duration 
TPOA T3 T4 TSH Thyroid status 
1 14 F 1 -- 1.1 4.7 2.7 euthyroid 
2 18 F 3 -- 1.4 5.6 0.9 euthyroid 
3 20 F 2 -- 0.8 8.1 3.1 euthyroid 
4 24 M 7 -- 0.9 9 4.4 euthyroid 
5 17 F 1 + 0.8 4.6 9.4 hypothyroid 
6 23 M 5 -- 1.1 7.1 2.8 euthyroid 
7 15 F 4.5 -- 0.8 5.4 3.7 euthyroid 
8 22 M 3.5 -- 1.4 4.6 1.4 euthyroid 
9 21 F 0.5 + 1.2 7 1.8 euthyroid 
10 18 M 2.5 -- 0.8 10 4.8 euthyroid 
11 27 F 4 + 0.9 5.2 7.2 hypothyroid 
12 14 M 1 -- 1.1 4.4 0.8 euthyroid 
13 13 M 0.25 -- 0.9 9.2 3.4 euthyroid 
14 18 F 4 -- 1.3 4.8 4.4 euthyroid 
15 17 M 2 -- 0.8 8.2 2.2 euthyroid 
16 19 F 1.5 -- 1.3 9.1 1.6 euthyroid 
17 17 M 3 -- 1.2 7.7 2.9 euthyroid 
18 17 M 2.5 -- 1.8 10.5 2.9 euthyroid 
19 20 F 2.5 -- 0.9 6.5 1.9 euthyroid 
20 20 M 1 -- 1.1 6.3 3.9 euthyroid 
21 15 F 1.25 -- 1.4 8.4 4.8 euthyroid 
22 21 M 1.5 -- 0.8 6.2 1 euthyroid 
23 14 M 1 -- 0.9 4.9 2.6 euthyroid 
24 16 F 4 + 1 4.6 4.7 euthyroid 
25 24 F 5 -- 1.3 10 4.4 euthyroid 
26 22 M 4 -- 1.2 7.3 3.8 euthyroid 
27 21 F 3 -- 0.8 5.4 3 euthyroid 
28 18 M 2 -- 1.1 4.3 2.8 euthyroid 
29 14 F 0.25 + 1 5.2 4.1 euthyroid 
30 20 F 3 -- 0.8 6.6 3 euthyroid 
31 15 F 1 -- 1.1 8.6 3.4 euthyroid 
32 18 M 2 + 0.8 5.4 9.8 hypothyroid 
33 20 M 3 -- 1.2 5.9 1.9 euthyroid 
  
 
 
34 23 M 5 -- 1.1 6.7 1 euthyroid 
35 32 F 4 -- 0.9 10.2 4.5 euthyroid 
36 29 M 5 -- 1.2 7.6 2.7 euthyroid 
37 26 M 6 + 0.8 7.2 4 euthyroid 
38 14 F 1.5 -- 1 9.4 3.2 euthyroid 
39 15 F 2 -- 1.1 8.8 2.6 euthyroid 
40 19 F 4 + 0.9 5.1 9 hypothyroid 
41 21 M 2 -- 1.3 4.2 3.8 euthyroid 
42 13 M 0.5 -- 1.2 10 2.8 euthyroid 
43 32 F 9 -- 1.1 6.7 4.4 euthyroid 
44 30 M 9 + 1 4.8 3.8 euthyroid 
45 14 M 4 -- 1.2 4.5 4.1 euthyroid 
46 20 F 5 -- 0.8 5.4 2.4 euthyroid 
47 31 M 6 -- 1.3 7.8 3.6 euthyroid 
48 29 F 6 -- 1.4 6.1 3.9 euthyroid 
49 26 F 12 + 0.4 3 36.2 hypothyroid 
50 25 M 4 -- 1.1 9.2 3.2 euthyroid 
51 15 F 5 -- 1 8.6 4.2 euthyroid 
52 13 M 0.5 -- 1.2 8.2 4.1 euthyroid 
53 18 F 2.5 -- 0.9 8.6 1.8 euthyroid 
54 19 F 1 -- 1.3 5.5 3.8 euthyroid 
55 14 F 3.5 + 0.8 6.1 8 hypothyroid 
56 18 M 2 -- 1.2 8.1 2.5 euthyroid 
57 20 F 2 -- 1 4.9 9.4 hypothyroid 
58 27 M 3 -- 1.1 10.2 4.2 euthyroid 
59 26 M 7 + 1 6.8 10 hypothyroid 
60 21 F 4.5 -- 1.4 9.9 0.9 euthyroid 
61 18 F 4 -- 0.9 11 1.8 euthyroid 
62 22 M 4 -- 1.2 5.4 3.8 euthyroid 
63 21 M 1 -- 1.1 6.4 3.7 euthyroid 
64 30 F 7 -- 0.9 4.6 4.4 euthyroid 
 
 
 
                                 
 
  
 
 
                             
  ABBREVIATIONS 
 
 
T1D                         :   TYPE 1 DIABETES MELLITUS 
AITD                       :   AUTOIMMUNE THYROID DISEASE 
TPOA                      :   THYROID PEROXIDASE ANTIBODY 
T3                            :   TRI-IODOTHYRONINE  
T4                            :    THYROXINE    
TSH                         :   THYROID STIMULATING HORMONE 
TRH                         :   THYROTROPIN RELEASING HORMONE 
TG AB                     :   THYROGLOBULIN ANTIBODY 
CD                           :   COELIAC DISEASE 
AD                           :   ADDISONS DISEASE 
HLA                        :   HUMAN LEUKOCYTE ANTIGEN 
APS                     :   AUTOIMMUNE  
                                     POLYENDOCRINE SYNDROME  
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